Hospital Pharmacy Operations, Formulary Management, and Clinical Protocols

Administrative Structure and Learning Outcomes

  • Key Personnel:

    • Jenna Maker
    • Sara Mahmoud
  • Core Clinical Competencies:

    • Application of common hospital processes to patient care, including order sets, protocols, clinical practice guidelines, antibiograms, and health system formularies.
    • Entry, evaluation, and verification of electronic medication orders.
    • Documentation of pharmacist clinical interventions within patient electronic health records.
    • Execution of medication reconciliation processes and comprehensive discharge medication counseling.
    • Utilization of proper aseptic technique for the compounding of sterile intravenous medications.
    • Delivery of oral and written medication counseling to hospitalized patients preparing for discharge.
  • Platform Requirements:

    • Access to EHR-Go learning software.
    • Access to Penguin software.
    • Schedule details hosted on Canvas.
  • Grading Assessment Scheme:

    • In-class assignments and quizzes: 50%50\% of final grade.
    • Aseptic Technique Objective Structured Clinical Examination (OSCE): 30%30\% of final grade.
    • Discharge Counseling OSCE: 20%20\% of final grade.

Hospital Pharmacy Scope of Practice and Inpatient Clinical Services

  • Inpatient Clinical Services Managed by Pharmacists:

    • Medication order entry and verification.
    • Pharmacokinetic dosing and monitoring: Vancomycin PK/AUC determinations and aminoglycoside monitoring.
    • Anticoagulant management protocols: Heparin continuous IV infusions, warfarin dosing, argatroban monitoring, and direct oral anticoagulant (DOAC) protocols.
    • Total Parenteral Nutrition (TPN) formulation and management protocols.
    • Antimicrobial Stewardship Programs (ASP).
    • Protocol Autonomy: Clinical pharmacists operate relatively independently under hospital-approved protocols to execute these clinical services.
  • Secondary Clinical and Administrative Responsibilities:

    • Transitions of Care (TOC): Conducting medication reconciliations and discharge counseling.
    • Educational Delivery: Conducting formal and informal drug education for pharmacy staff, medical staff, and nursing personnel.
    • Regulatory Adherence: Ensuring operational compliance with standards established by The Joint Commission, State Boards of Pharmacy, the Drug Enforcement Administration (DEA), and internal hospital policies and procedures.
    • Committee Representation: Active involvement in interprofessional committees, including Pharmacy and Therapeutics (P&T) and Infection Control committees.
    • Emergency Response: Functioning as primary responders to hospital emergency calls requiring a licensed pharmacist, such as Code Blue resuscitation events.
    • Clinical Specialization: Advanced practice involvement in specialized clinical areas including Oncology, Infectious Diseases (ID), and Intensive Care Units (ICU).

Formulary Structure and Governance

  • ASHP Definition of Formulary:

    • A formulary is a continually updated list of available medications and related information, representing the clinical judgment, resulting from a review of the clinical evidence, of clinicians in the diagnosis, prophylaxis, or treatment of disease and promotion of health.
  • Operational Definition:

    • A formulary represents the explicit list of pharmaceutical agents routinely stocked and maintained within a healthcare system.
  • Formulary Governance:

    • The Pharmacy & Therapeutics (P&T) committee is the organizational body responsible for developing, managing, evaluating, and updating the health system formulary.
  • Prescribing and Dispensing Restrictions:

    • Prescribing Criteria Restrictions: Requirement for patients to meet established clinical criteria prior to drug dispensing. Example: Aztreonam is restricted solely to patients with a documented, severe anaphylactic allergy to beta-lactam antibiotics.
    • Medical Service Restrictions: Requirement for specific specialist service authorization prior to medication approval. Example: Amphotericin B requires Infectious Diseases (ID) consult approval.
    • Patient Care Area Restrictions: Dispensing limited to specific physical patient units. Example: Neuromuscular blocking agents are restricted to the Operating Room (OR) and Intensive Care Units (ICU).
  • Non-Formulary (NF) Medication Protocols:

    • Operational Framework: Formal exception processes exist to request and acquire non-formulary agents when specific, unique clinical needs cannot be met using standard formulary drugs.
    • Clinical Justifications: Documented severe drug allergy to all formulary options, or documented therapeutic failure on formulary alternatives.
    • Operational Verification Workflow:
    • Confirm whether the non-formulary agent is physically in stock or requires external ordering (identifying potential dispensing delays).
    • Assess whether the patient can utilize their personal home medication supply under hospital custody guidelines.

Master Health System Formulary Sample Reference

  • iron sucrose (Venofer):

    • Pharmacologic Class: Hematology-Oncology, Nutrition-Iron Homeostasis, Minerals.
    • Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
  • isoflurane (Forane):

    • Pharmacologic Class: Anesthesia, Anesthetics (General).
    • Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
  • isoniazid PO (Generic):

    • Pharmacologic Class: Antimicrobials, Tuberculosis (TB).
    • Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Formulary.
  • isoproterenol (Isuprel):

    • Pharmacologic Class: Cardiovascular, Antiarrhythmics (Parenteral).
    • Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
  • isosorbide dinitrate (Isordil):

    • Pharmacologic Class: Cardiovascular, Vasodilators/Nitrates.
    • Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
  • isosorbide mononitrate (Generic):

    • Pharmacologic Class: Cardiovascular, Vasodilators/Nitrates.
    • Status: Inpatient = Formulary; Clinic = Other; Custody = Non-formulary; Outpatient = Formulary.
  • isosulfan blue 1% (Generic):

    • Pharmacologic Class: Diagnostic.
    • Status: Inpatient = Restricted; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
    • Specific Restrictions: Restricted to Operating Room use only.
  • isotretinoin (Accutane):

    • Pharmacologic Class: Dermatologic, Acne (Systemic).
    • Status: Inpatient = Restricted; Clinic = Restricted; Custody = Restricted; Outpatient = Restricted.
    • Specific Restrictions: 10 mg10\,\text{mg} and 40 mg40\,\text{mg} capsules only; restricted to Dermatology services.
  • isradipine (Generic):

    • Pharmacologic Class: Cardiovascular, Calcium Channel Blockers (Dihydropyridine).
    • Status: Inpatient = Restricted; Clinic = Restricted; Custody = Non-formulary; Outpatient = Restricted.
    • Specific Restrictions: Pediatric Specialty Clinic use limited to pediatric patients; Inpatient use limited to Pediatric and Pediatric Intensive Care Unit (PICU) floors.
  • itraconazole (Generic):

    • Pharmacologic Class: Antimicrobials, Dental-Oral Care Antifungals, Candidiasis (Oropharyngeal).
    • Status: Inpatient = Restricted; Clinic = Non-formulary; Custody = Non-formulary; Outpatient = Formulary.
    • Specific Restrictions: Refer to Enterprise policy #0009 Inpatient Restricted.
  • ivermectin (Stromectol):

    • Pharmacologic Class: Antimicrobials, Antiparasitics.
    • Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
  • ketamine (Generic, Ketalar):

    • Pharmacologic Class: Anesthesia, Anesthetics (General), Sedation.
    • Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
  • ketoconazole (Generic):

    • Pharmacologic Class: Antimicrobials, Antifungals.
    • Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Non-formulary.
  • ketoconazole topical (Nizoral Topical):

    • Pharmacologic Class: Antimicrobials, Dermatologic, Antifungals (Topical), Seborrhea/Dandruff.
    • Status: Inpatient = Formulary; Clinic = Formulary; Custody = Formulary; Outpatient = Formulary.

Antimicrobial Stewardship Tier Categorization

  • Tier Definitions and Approval Framework:

    • Tier 1 (Infectious Diseases Restriction): Full restriction to the Infectious Disease (ID) service. Requires direct pre-approval from the ID Consult Service or the Antimicrobial Stewardship Program (ASP) Service.
    • Tier 2 (Pharmacy Approval): Pharmacy approval may be granted for clinical scenarios meeting specific pre-approved criteria. Unapproved scenarios require formal authorization from ID or the ASP Service within 72 hours72\,\text{hours}.
    • Tier 3 (Protected): Unrestricted agents that undergo routine retrospective review by the ASP Service.
    • Tier 4 (Unrestricted): Unrestricted agents that are not regularly reviewed by the ASP Service.
  • Tier Classification Table:

    • Tier 1 Agents (ID Restriction):
    • Caspofungin (Non-formulary)
    • Ceftaroline (Non-formulary)
    • Ceftazidime/avibactam (Non-formulary)
    • Ceftolozane/tazobactam (Non-formulary)
    • Colistimethate intravenous (Restricted)
    • Dalbavancin (Non-formulary)
    • Delafloxacin (Non-formulary)
    • Eravacycline (Restricted)
    • Flucytosine (Restricted)
    • Foscarnet (Non-formulary)
    • Isavuconazole (Non-formulary)
    • Meropenem/vaborbactam (Non-formulary)
    • Quinupristin/dalfopristin (Restricted)
    • Imipenem/cilastatin/relabactam (Restricted)
    • Streptomycin (Non-formulary)
    • Omadecycline (Non-formulary)
    • Oritavancin (Non-formulary)
    • Plazomicin (Non-formulary)
    • Polymyxin B intravenous (Non-formulary)
    • Tigecycline (Non-formulary)
    • Tier 2 Agents (Pharmacy Approval):
    • Amphotericin B lipid formulation (Abelcet or Ambisome) (Restricted)
    • Aztreonam (Restricted)
    • Daptomycin (Restricted)
    • Ertapenem (Restricted)
    • Fidaxomicin (Restricted)
    • Fosfomycin (Restricted)
    • Ganciclovir (Restricted)
    • Imipenem/cilastatin (Restricted)
    • Itraconazole (Restricted)
    • Linezolid (Restricted)
    • Meropenem (Restricted)
    • Micafungin (Restricted)

Tier 2 Antimicrobial Usage Criteria

  • Amphotericin B Lipid Formulation (Abelcet or Ambisome):

    • Pre-approved Indications (must meet at least one):
    • Candidal endophthalmitis, endocarditis, or central nervous system infection.
    • Cryptococcal meningitis.
    • Zygomycoses.
    • Neutropenic Fever accompanied by a documented fungal infection or failure of empiric antibacterial therapy.
    • Severe coccidioidomycosis infections.
    • Disseminated histoplasmosis infections.
    • Alternative agent for invasive aspergillosis.
    • Alternative agent for candidemia.
    • Unacceptable Usage Criteria:
    • Management of Candida infections susceptible to alternative agents.
  • Aztreonam:

    • Pre-approved Indications:
    • Severe, documentable allergy (e.g., anaphylaxis) to all other beta-lactam classes, including penicillins, cephalosporins, and carbapenems.
  • Daptomycin:

    • Pre-approved Indications (must meet at least one):
    • Vancomycin allergy combined with bacteremia caused by MRSA/Coagulase Negative Staphylococcus spp. (CONS) or endocarditis caused by MRSA/CONS.
    • Infections caused by Vancomycin-Resistant S. aureus (VRSA).
    • MRSA bacteremia or endocarditis in patients failing vancomycin therapy, where failure is defined as:
      • Clinical decompensation after 3−4 days3-4\,\text{days} of therapy.
      • Persistent bacteremia despite 7 days7\,\text{days} of vancomycin therapy with documented serum troughs of 15−20 mcg/mL15-20\,\text{mcg/mL}.
      • Vancomycin MIC > 2 mcg/mL2\,\text{mcg/mL} (requires ID notification).
    • Continuation of daptomycin therapy initiated at an outside transfer facility.
    • Bone and joint infections supported by documented MRSA culture (excluding screening swabs).
    • Unacceptable Usage Criteria (must not meet any):
    • Treatment of pneumonia, due to drug inactivation by pulmonary surfactant.
    • Initial empiric therapy for Gram-positive infections (excluding patients transferred from an outside hospital on established daptomycin therapy).
    • Vancomycin-Resistant Enterococcus (VRE) colonization isolated from urine, respiratory tract, wounds, or surgical drains.
  • Ertapenem:

    • Pre-approved Indications (must meet all criteria):
    • Documented infection caused by an extended-spectrum beta-lactamase (ESBL) producing organism.
    • ESBL isolate confirmed susceptible to ertapenem via laboratory testing.

Therapeutic Interchange Regulations and Execution

  • Definition and Scope:

    • Therapeutic interchange involves dispensing a medication that is therapeutically equivalent to the original medication ordered by a prescriber.
    • Authorizes pharmacists to automatically substitute a formulary therapeutic alternative in place of a non-formulary drug or a non-preferred formulary agent without prior prescriber contact.
    • Exceptions to standard interchange protocols include drug backorders or authorization for a patient to use their personal home medication supply.
  • Clinical Verification Responsibilities:

    • Pharmacists must exercise independent clinical judgment and refrain from executing a therapeutic interchange if specific patient contraindications or clinically significant drug-drug interactions (DDIs) exist.
    • The evaluating pharmacist is required to consult drug reference materials to determine maximum dosing limits and renal dose adjustments prior to processing an interchange.
    • Critical product categories requiring heightened monitoring during evaluation include:
    • Biosimilars.
    • Immediate-Release (IR) versus Extended-Release (ER) or Controlled-Release (CR) formulations.
    • Fixed-dose combination products.

Angiotensin II Receptor Antagonist Therapeutic Interchange Guidelines

  • Interchange Formatting Rules:

    • BOLD text denotes formulary status.
    • PREFERRED indicates the first-line formulary selection. Non-preferred formulary options may be used if preferred options are unavailable or contraindicated due to allergy or intolerance.
    • Non-formulary options are reserved for special circumstances such as manufacturer backorders.
  • Heart Failure Protocol (HFrEF Specific):

    • Scope: Applies to patients with Heart Failure with reduced Ejection Fraction (HFrEF). Interchanges are strictly limited to Losartan, Candesartan, and Valsartan.
    • Bi-directional Dose Equivalencies (Once Daily Only):
    • Losartan (Cozaar) 25 mg25\,\text{mg} (PREFERRED) ↔\leftrightarrow Valsartan (Diovan) 40 mg40\,\text{mg} (FORMULARY) ↔\leftrightarrow Candesartan (Atacand) 4 mg4\,\text{mg} (NON-PREFERRED).
    • Losartan (Cozaar) 50 mg50\,\text{mg} (PREFERRED) ↔\leftrightarrow Valsartan (Diovan) 80 mg80\,\text{mg} (FORMULARY) ↔\leftrightarrow Candesartan (Atacand) 8 mg8\,\text{mg} (NON-PREFERRED).
    • Losartan (Cozaar) 100 mg100\,\text{mg} (PREFERRED) ↔\leftrightarrow Valsartan (Diovan) 160 mg160\,\text{mg} (FORMULARY) ↔\leftrightarrow Candesartan (Atacand) 16 mg16\,\text{mg} (NON-PREFERRED).
    • Valsartan (Diovan) 320 mg320\,\text{mg} (FORMULARY) ↔\leftrightarrow Candesartan (Atacand) 32 mg32\,\text{mg} (NON-PREFERRED).
  • Non-Heart Failure Indications Protocol:

    • Scope: Applies solely to non-heart failure indications. Irbesartan and Olmesartan are not indicated for heart failure and cannot be used in HFrEF patients.
    • Bi-directional Dose Equivalencies (Once Daily Only):
    • Losartan 25 mg25\,\text{mg} (PREFERRED) ↔\leftrightarrow Valsartan 40 mg40\,\text{mg} (FORMULARY) ↔\leftrightarrow Candesartan 4 mg4\,\text{mg} (NON-PREFERRED) ↔\leftrightarrow Olmesartan (Benicar) 5 mg5\,\text{mg} (NON-PREFERRED) ↔\leftrightarrow Irbesartan (Avapro) 75 mg75\,\text{mg} (NON-PREFERRED).
    • Losartan 50 mg50\,\text{mg} (PREFERRED) ↔\leftrightarrow Valsartan 80 mg80\,\text{mg} (FORMULARY) ↔\leftrightarrow Candesartan 8 mg8\,\text{mg} (NON-PREFERRED) ↔\leftrightarrow Olmesartan 20 mg20\,\text{mg} (NON-PREFERRED) ↔\leftrightarrow Irbesartan 150 mg150\,\text{mg} (NON-PREFERRED).
    • Losartan 100 mg100\,\text{mg} (PREFERRED) ↔\leftrightarrow Valsartan 160 mg160\,\text{mg} (FORMULARY) ↔\leftrightarrow Candesartan 16 mg16\,\text{mg} (NON-PREFERRED) ↔\leftrightarrow Olmesartan 40 mg40\,\text{mg} (NON-PREFERRED) ↔\leftrightarrow Irbesartan 300 mg300\,\text{mg} (NON-PREFERRED).
    • Valsartan 320 mg320\,\text{mg} (FORMULARY) ↔\leftrightarrow Candesartan 32 mg32\,\text{mg} (NON-PREFERRED).

Clinical Antibiograms and Infectious Disease Workflow

  • Antibiogram Definition and Purpose:

    • An antibiogram is a periodic report summarizing aggregate antimicrobial susceptibilities of local bacterial isolates analyzed by a institutional microbiology laboratory.
    • Functions:
    • Evaluation of local bacterial susceptibility rates.
    • Selection guidance for empiric antimicrobial therapy prior to culture confirmation.
    • Long-term monitoring of resistance pattern trends within an institution.
  • Organizational Structure of Antibiograms:

    • Antibiograms are facility-specific and typically updated on an annual basis.
    • Data is stratified by clinical care setting:
    • Inpatient medical/surgical floors.
    • Outpatient departments / Emergency Room (ER).
    • Intensive Care Units (ICU).
    • Certain reports isolate urinary tract specimens from non-urinary tract specimens.
  • Clinical Infection Management Workflow:

    • Step 1: Patient develops clinical signs and symptoms of infection.
    • Step 2: Microbiological cultures are collected and submitted to the laboratory.
    • Step 3: Patient is initiated on EMPIRIC antibiotic therapy. Antibiograms are utilized directly at this step to guide empiric drug selection based on local susceptibility patterns.
    • Step 4: Cultures successfully isolate the causative microorganism and susceptibility profiles are determined.
    • Step 5: Patient is transitioned to DEFINITIVE antibiotic therapy tailored specifically to the isolated pathogen.

Institutional Antibiogram Reference Data

  • Dataset Overview:

    • Reporting Period: 01/01/2021 to 12/31/2021.
    • Laboratory Supervision: Stuart Cohen, M.D., Director, Clinical Microbiology Laboratory (UC Davis Health Antimicrobial Stewardship Program).
    • Target Population/Setting: Pediatric Inpatient ICU - Gram Positive Organisms.
  • Antimicrobial Susceptibility Percentages (Percent of Isolates Susceptible\text{Percent of Isolates Susceptible}):

    • Staphylococcus aureus, all (n=42n = 42):

    • Erythromycin: 80%80\%

    • Clindamycin: 80%80\%

    • Levofloxacin: 59%59\%

    • Tetracycline: 78%78\%

    • Minocycline: 87%87\%

    • Gentamicin: 96%96\%

    • Daptomycin: 100%100\%

    • Linezolid: 100%100\%

    • Rifampin: 100%100\%

    • Trimethoprim/Sulfamethoxazole: 100%100\%

    • Vancomycin: 100%100\%

    • Staphylococcus aureus, MSSA (n=34n = 34):

    • Oxacillin: 100%100\%

    • Cefazolin: 100%100\%

    • Erythromycin: 100%100\%

    • Clindamycin: 97%97\%

    • Levofloxacin: 19%19\%

    • Trimethoprim/Sulfamethoxazole: 100%100\%

    • Vancomycin: 100%100\%

    • Staphylococcus aureus, MRSA (n=8n = 8):

    • Oxacillin: 0%0\%

    • Cefazolin: 0%0\%

    • Erythromycin: 0%0\%

    • Clindamycin: 100%100\%

    • Levofloxacin: 20%20\%

    • Tetracycline: 20%20\%

    • Minocycline: 80%80\%

    • Gentamicin: 80%80\%

    • Daptomycin: 100%100\%

    • Linezolid: 100%100\%

    • Rifampin: 100%100\%

    • Trimethoprim/Sulfamethoxazole: 100%100\%

    • Vancomycin: 100%100\%

    • Coagulase Negative Staphylococci (n=12n = 12):

    • Oxacillin susceptibility documented per Clinical and Laboratory Standards Institute (CLSI) breakpoints (2 mcg/mL2\,\text{mcg/mL} for Staph spp; 0.5 mcg/mL0.5\,\text{mcg/mL} for CONS).

    • Enterococcus species, all (n=26n = 26):

    • Penicillin G: 79%79\%

    • Ampicillin: 92%92\%

    • Gentamicin (High Level): 75%75\%

    • Streptomycin (High Level): 50%50\%

    • Daptomycin: 75%75\%

    • Linezolid: 100%100\%

    • Vancomycin: 100%100\%

    • Enterococcus faecalis (n=18n = 18):

    • Penicillin G: 100%100\%

    • Ampicillin: 100%100\%

    • Linezolid: 100%100\%

    • Vancomycin: 100%100\%

    • Enterococcus faecium (n=18n = 18):

    • Penicillin G: 100%100\%

    • Ampicillin: 100%100\%

    • Linezolid: 100%100\%

    • Vancomycin: 100%100\%